A chronic disappointment for Viridian
Without full placebo data, it is hard to handicap VRDN-001’s chances in thyroid eye disease.
Go or no go? Decision day looms for Eisai and Biogen
Leqembi seeks full approval, while Takeda hopes for a dengue green light and Verrica looks to break its streak of bad luck.
Pfizer posts another haemophilia hit
The group is taking marstacimab to the regulators, but Novo’s MAb looks like a bad omen.
Asco 2023 – Regeneron nips at Bristol’s heels in Lag3
Fianlimab continues to look like biopharma’s leading Lag3 asset, with activity in a new melanoma setting to boot.
Archer misses the target
Annexon’s failure in geographic atrophy could clear the way for its rivals.
Here come the PD-1 agonists
Lilly shows that peresolimab is a goer, and others are not far behind; but what about the cancer risk?
ESPID 2023 – hospitalisation data in tune for Beyfortus
The Harmonie trial shows a hospitalisation benefit where Melody could not.